LARIMAR THERAPEUTICS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2026-03-31 was $107.62M.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2025-09-30 was $65.04M.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2024-03-31 was $161.76M.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, new issues for the quarter ending 2022-09-30 was $75.24M, a 278.39% increase year-over-year.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2025 was $65.04M, a 59.79% decline from fiscal 2024.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2024 was $161.76M.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2022 was $75.26M, a 278.46% increase from fiscal 2021.
- LARIMAR THERAPEUTICS, INC. stock issued during period, value, new issues for fiscal 2021 was $19.89M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-03-31 | $107.62M 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $65.04M 10-K · filed 2026-03-19 | |
| 2025-09-30 | $65.04M 10-Q · filed 2025-11-05 | |
| 2024-12-31 | $161.76M 10-K · filed 2026-03-19 | |
| 2024-03-31 | $161.76M 10-Q · filed 2025-11-05 | |
| 2022-12-31 | $75.26M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $75.24M 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $19.89M 10-K · filed 2023-03-14 | |
| 2021-09-30 | $19.89M 10-Q · filed 2022-11-10 | |
| 2018-12-31 | $64.41M 10-K · filed 2020-03-05 | |
| 2018-09-30 | $64.56M 10-Q · filed 2019-11-06 | |
| 2016-12-31 | $35.00K 10-K · filed 2019-03-14 | |
| 2015-12-31 | $129.57M 10-K · filed 2018-03-09 | |
| 2014-12-31 | $100.16M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |